Michael S. Chambers

Array ( [id] => 20541250 [patent_doc_number] => 20260048138 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-02-19 [patent_title] => NOVEL PI3K AND/OR PIKK INHIBITORS, ANTIBODY-DRUG CONJUGATES COMPRISING THE SAME AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 19/374186 [patent_app_country] => US [patent_app_date] => 2025-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37846 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19374186 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20458345 [patent_doc_number] => 20260007765 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-01-08 [patent_title] => ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPING [patent_app_type] => utility [patent_app_number] => 19/329403 [patent_app_country] => US [patent_app_date] => 2025-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30315 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19329403 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20472048 [patent_doc_number] => 20260014266 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-01-15 [patent_title] => COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY [patent_app_type] => utility [patent_app_number] => 19/263372 [patent_app_country] => US [patent_app_date] => 2025-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34363 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19263372 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20419200 [patent_doc_number] => 20250381285 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-18 [patent_title] => COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY [patent_app_type] => utility [patent_app_number] => 19/263325 [patent_app_country] => US [patent_app_date] => 2025-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33962 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19263325 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20459432 [patent_doc_number] => 20260008855 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-01-08 [patent_title] => KLRB1 BINDING AGENTS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 19/259911 [patent_app_country] => US [patent_app_date] => 2025-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27562 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19259911 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20562937 [patent_doc_number] => 12565538 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-03 [patent_title] => FCRN/antigen-binding molecules and methods of use [patent_app_type] => utility [patent_app_number] => 19/256452 [patent_app_country] => US [patent_app_date] => 2025-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 35 [patent_no_of_words] => 65235 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19256452 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20756249 [patent_doc_number] => 12648998 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2026-06-09 [patent_title] => Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping [patent_app_type] => utility [patent_app_number] => 19/234136 [patent_app_country] => US [patent_app_date] => 2025-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 14 [patent_no_of_words] => 29849 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19234136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20163936 [patent_doc_number] => 20250255982 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-14 [patent_title] => ANTI-MUC1* ANTIBODY DRUG COMPLEXES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 19/098785 [patent_app_country] => US [patent_app_date] => 2025-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35063 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19098785 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20099021 [patent_doc_number] => 20250228957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-17 [patent_title] => BIFUNCTIONAL DEGRADERS OF GALACTOSE-DEFICIENT IMMUNOGLOBULINS [patent_app_type] => utility [patent_app_number] => 19/060384 [patent_app_country] => US [patent_app_date] => 2025-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26868 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19060384 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20757037 [patent_doc_number] => 12649796 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-06-09 [patent_title] => N-terminal scFv multispecific binding molecules [patent_app_type] => utility [patent_app_number] => 19/035322 [patent_app_country] => US [patent_app_date] => 2025-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 31 [patent_no_of_words] => 19848 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19035322 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20608320 [patent_doc_number] => 12583908 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-24 [patent_title] => Albumin protein variants, production thereof and uses of same [patent_app_type] => utility [patent_app_number] => 19/023442 [patent_app_country] => US [patent_app_date] => 2025-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 34 [patent_no_of_words] => 11184 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19023442 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20068625 [patent_doc_number] => 20250206847 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-26 [patent_title] => DIMERIC ANTIBODIES AND THEIR METHODS OF MANUFACTURE [patent_app_type] => utility [patent_app_number] => 19/002112 [patent_app_country] => US [patent_app_date] => 2024-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11726 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 311 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19002112 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19876951 [patent_doc_number] => 20250109208 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-03 [patent_title] => Antibodies Targeting ActRIIA and ActRIIB [patent_app_type] => utility [patent_app_number] => 18/945784 [patent_app_country] => US [patent_app_date] => 2024-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33829 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18945784 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19916225 [patent_doc_number] => 12291579 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-06 [patent_title] => Anti-phosphocholine antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 18/920412 [patent_app_country] => US [patent_app_date] => 2024-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38677 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18920412 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19830984 [patent_doc_number] => 20250082770 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-13 [patent_title] => ANTIBODY-CONJUGATES FOR TARGETING OF TUMOURS EXPRESSING CARCINOEMBYRONIC ANTIGEN [patent_app_type] => utility [patent_app_number] => 18/892256 [patent_app_country] => US [patent_app_date] => 2024-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31492 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18892256 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19477511 [patent_doc_number] => 20240325553 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-03 [patent_title] => CYTOSTATIC CONJUGATES WITH INTEGRIN LIGANDS [patent_app_type] => utility [patent_app_number] => 18/744084 [patent_app_country] => US [patent_app_date] => 2024-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10082 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18744084 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19657060 [patent_doc_number] => 20240424125 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-26 [patent_title] => ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/677564 [patent_app_country] => US [patent_app_date] => 2024-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 78429 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18677564 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19526746 [patent_doc_number] => 20240350648 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => INTRACELLULAR DELIVERY COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 18/653316 [patent_app_country] => US [patent_app_date] => 2024-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45139 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18653316 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19586450 [patent_doc_number] => 20240384007 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-21 [patent_title] => COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION [patent_app_type] => utility [patent_app_number] => 18/629314 [patent_app_country] => US [patent_app_date] => 2024-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 145061 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18629314 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19512116 [patent_doc_number] => 20240343802 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs [patent_app_type] => utility [patent_app_number] => 18/612960 [patent_app_country] => US [patent_app_date] => 2024-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43258 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18612960 [rel_patent_id] =>[rel_patent_doc_number] =>)